3 No-Brainer Stocks to Buy for Under $100 Right Now
https://www.fool.com/investing/2024/06/22/3-no-brainer-stocks-to-buy-for-under-100-right-now/?source=iedfolrf0000001
Jun 22, 2024 - You won't need much money to start investing in these great stocks.
0
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
https://www.zacks.com/stock/news/2291505/pharma-stock-roundup-fda-nod-to-mrk-s-new-jab-expanded-use-of-abbv-azn-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2291505
Jun 21, 2024 - FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
0
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
https://www.zacks.com/stock/news/2290954/astrazeneca-s-azn-truqap-gets-eu-nod-for-breast-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290954
Jun 20, 2024 - The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
0
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
https://www.zacks.com/stock/news/2290616/ionis-ions-expands-licensing-deal-with-otsuka-for-hae-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290616
Jun 19, 2024 - Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
0
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2288493/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2288493
Jun 14, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2287262/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2287262
Jun 12, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2286344/astrazeneca-azn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2286344
Jun 10, 2024 - In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.
0
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
https://www.zacks.com/stock/news/2285380/pharma-stock-roundup-lly-s-cfo-departs-abbv-azn-drugs-get-chmp-approval?cid=CS-ZC-FT-analyst_blog|stock_roundup-2285380
Jun 07, 2024 - Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
0
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
https://www.fool.com/investing/2024/06/03/the-gold-rush-for-weight-loss-drugs-is-here-these/?source=iedfolrf0000001
Jun 03, 2024 - There's probably a big enough pie here for everyone to get a slice.
0
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
https://www.zacks.com/stock/news/2281925/pharma-stock-roundup-jnj-mrk-m-a-deals-sny-rhhby-drugs-priority-review-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2281925
May 31, 2024 - J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
0